| LPA receptors: subtypes and biological actions JW Choi, DR Herr, K Noguchi, YC Yung, CW Lee, T Mutoh, ME Lin, ... Annual review of pharmacology and toxicology 50 (1), 157-186, 2010 | 1016 | 2010 |
| FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation JW Choi, SE Gardell, DR Herr, R Rivera, CW Lee, K Noguchi, ST Teo, ... Proceedings of the National Academy of Sciences 108 (2), 751-756, 2011 | 688 | 2011 |
| Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family K Noguchi, S Ishii, T Shimizu Journal of Biological Chemistry 278 (28), 25600-25606, 2003 | 688 | 2003 |
| Lysophosphatidic acid (LPA) and its receptors K Noguchi, D Herr, T Mutoh, J Chun Current opinion in pharmacology 9 (1), 15-23, 2009 | 288 | 2009 |
| LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis H Sumida, K Noguchi, Y Kihara, M Abe, K Yanagida, F Hamano, S Sato, ... Blood, The Journal of the American Society of Hematology 116 (23), 5060-5070, 2010 | 183 | 2010 |
| Lysophosphatidic acid signaling may initiate fetal hydrocephalus YC Yung, T Mutoh, ME Lin, K Noguchi, RR Rivera, JW Choi, ... Science translational medicine 3 (99), 99ra87-99ra87, 2011 | 177 | 2011 |
| LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line K Yanagida, S Ishii, F Hamano, K Noguchi, T Shimizu Journal of Biological Chemistry 282 (8), 5814-5824, 2007 | 142 | 2007 |
| Non-Edg family lysophosphatidic acid (LPA) receptors S Ishii, K Noguchi, K Yanagida Prostaglandins & other lipid mediators 89 (3-4), 57-65, 2009 | 98 | 2009 |
| Stereotyped fetal brain disorganization is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling KJ Herr, DR Herr, CW Lee, K Noguchi, J Chun Proceedings of the National Academy of Sciences 108 (37), 15444-15449, 2011 | 76 | 2011 |
| Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport MPW Moos, JD Mewburn, FWK Kan, S Ishii, M Abe, K Sakimura, ... The FASEB Journal 22 (12), 4352-4362, 2008 | 58 | 2008 |
| Roles for lysophospholipid S1P receptors in multiple sclerosis K Noguchi, J Chun Critical reviews in biochemistry and molecular biology 46 (1), 2-10, 2011 | 33 | 2011 |
| Development of highly sensitive biosensors of RAF dimerization in cells K Miyamoto, M Sawa Scientific reports 9 (1), 636, 2019 | 11 | 2019 |
| Altered cleavage plane orientation with increased genomic aneuploidy produced by receptor-mediated lysophosphatidic acid (LPA) signaling in mouse cerebral cortical neural … WS McDonald, K Miyamoto, R Rivera, G Kennedy, BSV Almeida, ... Molecular Brain 13, 1-14, 2020 | 6 | 2020 |
| Trial in progress: a phase 1b study of AS-1763, an oral, potent and selective noncovalent BTK inhibitor, in patients with previously treated chronic lymphocytic leukemia/small … N Jain, J D'Olimpio, ST Lee, NN Shah, J Pinilla-Ibarz, CC Coombs, ... Blood 142, 3288, 2023 | 1 | 2023 |
| Lysophosphatidic acid receptor T Shimizu, S Ishii, K Noguchi US Patent 7,666,611, 2010 | 1 | 2010 |
| Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers N Timofeeva, B Herrera, SI Tantawy, H Fujiwara, L Loza, M Hatakeyama, ... Blood 144, 1850, 2024 | | 2024 |
| Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies N Jain, CC Coombs, J D'Olimpio, NN Shah, JC Barrientos, ST Lee, ... Blood 144, 1866, 2024 | | 2024 |
| Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study K Miyamoto, RM Miller, C Voors‐Pette, JAF Oosterhaven, ... Clinical and Translational Science 17 (11), e70060, 2024 | | 2024 |
| Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia SI Tantawy, N Timofeeva, H Fujiwara, M Hatakeyama, B Herrera, L Loza, ... Blood 142, 1453, 2023 | | 2023 |
| Abstract CT137: Safety, pharmacokinetics, and pharmacodynamics of AS-1763, a highly selective, orally bioavailable, non-covalent BTK inhibitor, in healthy volunteers A Arimura, K Miyamoto, M Velinova, M van den Dobbelsteen, K Mihara, ... Cancer Research 82 (12_Supplement), CT137-CT137, 2022 | | 2022 |